山东大学耳鼻喉眼学报 ›› 2024, Vol. 38 ›› Issue (1): 54-58.doi: 10.6040/j.issn.1673-3770.0.2022.329

• 论著 • 上一篇    下一篇

累及儿童多部位的浆细胞型Castleman病1例并文献复习

陈坤,陆慧,李磊,张帆,杨军,黄琦   

  1. 上海交通大学医学院附属新华医院 耳鼻咽喉头颈外科/上海交通大学医学院耳科学研究所/上海市耳鼻疾病转化医学重点实验室, 上海 200092
  • 发布日期:2024-01-12
  • 通讯作者: 黄琦. E-mail:huangqi3300@hotmail.com
  • 作者简介:陈坤、陆慧为共同第一作者

Multicentric plasma cell type Castleman disease involving multiple sites in children: a case report and literature review

CHEN Kun, LU Hui, LI Lei, ZHANG Fan, YANG Jun, HUANG Qi   

  1. Department of Otorhinolaryngology & Head and Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine/Shanghai Jiaotong University School of Medicine Ear Institute/Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases, Shanghai 200092, China
  • Published:2024-01-12

摘要: 目的 探讨多中心型Castleman病的临床表现、诊断依据、鉴别诊断和治疗方法。 方法 回顾性分析1例病理类型为浆细胞型的多中心型Castleman病患儿的临床资料,并对相关文献进行总结。 结果 多中心型Castleman病的发病机制尚不明确,通常无典型临床表现及病理特征,诊断极为困难。患儿治疗采用利妥昔单抗静滴,期间辅以地塞米松、抗生素和丙种球蛋白控制鼻部感染和渗出。治疗28 d后全身病损明显消退,血生化指标逐渐恢复,但嗜酸性粒细胞及炎症因子仍维持较高水平。随访13个月,患儿恢复良好,无不良反应及后遗症发生。 结论 多中心型Castleman病是一种罕见的淋巴增生性疾病,发生于鼻部的极为少见,目前的治疗方案主要针对于成人,儿童方面鲜有报道,仍需个性化制定治疗措施。对于难以手术切除和治疗效果不佳的患儿,利妥昔单抗是安全有效的治疗药物。

关键词: Castleman病, 儿童, 嗜酸性粒细胞, 炎症因子, 利妥昔单抗

Abstract: Objective To explore the pathogenesis, clinical presentation, diagnostic basis, differential diagnosis, and treatment options for multicentric Castleman disease. Methods Clinical data of a child diagnosed with multicentric Castleman disease of the plasma cell type were retrospectively analyzed, and the relevant literature was summarized. Results Multicentric Castleman disease is characterized by unclear pathogenesis and often lacks typical clinical manifestations and pathological features, making its diagnosis extremely challenging. In this case, the child received treatment with rituximab static drops, supplemented with dexamethasone, antibiotics, and gamma globulin to control the nasal infection and exudation. Following 28 days of treatment, the systemic disease subsided significantly and the blood biochemical index gradually recovered. After 13 months, the child had recovered well with no adverse effects or sequelae. Conclusion Multicentric Castleman disease is a rare lymphoproliferative disease, with rare occurrence in the nasal region. The current treatment plans mainly focus on adults, with limited reporting on children. Personalized treatment measures still need to be developed for children. Rituximab is a safe and effective treatment option for children with challenging surgical resection and unfavorable treatment outcomes.

Key words: Castleman disease, Child, Eosinophil, Inflammatory factors, Rituximab

中图分类号: 

  • R765
[1] Castleman B, Towne VW. Case records of the massachusetts general hospital; weekly clinicopathological exercises; founded by Richard C. Cabot[J]. N Engl J Med, 1954, 251(10): 396-400. doi:10.1056/NEJM195409022511008
[2] Raboso E, Barberá R, Guimaraens L, et al. Castleman's disease as an unusual cause for dysphagia and dyspnea in a pediatric patient[J]. Int J Pediatr Otorhinolaryngol, 2019, 125: 164-167. doi:10.1016/j.ijporl.2019.07.017
[3] van Rhee F, Munshi NC. Castleman Disease[J]. Hematol Oncol Clin North Am, 2018, 32(1): xiii-xiv. doi: 10.1016/j.hoc.2017.10.001
[4] Rabinowitz MR, Levi J, Conard K, et al. Castleman disease in the pediatric neck: a literature review[J]. Otolaryngol Head Neck Surg, 2013, 148(6): 1028-1036. doi:10.1177/0194599813479931
[5] 中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(7): 529-534. doi: 10.3760/cma.j.issn.0253-2727.2021.07.001
[6] Wang HB, Wieczorek RL, Zenilman ME, et al. Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome[J]. World J Surg Oncol, 2007, 5: 133. doi:10.1186/1477-7819-5-133
[7] Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions[J]. Adv Anat Pathol, 2009, 16(4): 236-246. doi:10.1097/PAP.0b013e3181a9d4d3
[8] Yoshizaki K, Murayama S, Ito H, et al. The role of interleukin-6 in castleman disease[J]. Hematol Oncol Clin North Am, 2018, 32(1): 23-36. doi:10.1016/j.hoc.2017.09.003
[9] Dispenzieri A, Fajgenbaum DC. Overview of castleman disease[J]. Blood, 2020, 135(16): 1353-1364. doi:10.1182/blood.2019000931
[10] Anon. NCCN guidelines version 5. 2021: B-Cell lymphomas[EB/OL].(2021-09-22)[2022-08-29]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480
[11] Health China N. National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China(English version)[J]. Chin J Cancer Res, 2022, 34(5): 425-446. doi:10.21147/j.issn.1000-9604.2022.05.01
[1] 李凯,罗丹. 润目灵方激活LC3-ATG5自噬通路抑制炎症因子表达改善干眼大鼠眼表损伤的机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 92-101.
[2] 朱希倩,王佳,孙祖贤,冯建秀,张梦佳,赵颖,王宏,姜敏敏. 上海市杨浦区2022—2024年6~9岁学龄儿童屈光状态分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 102-109.
[3] 宋艳玲,司元元,崔彦. 微量玻璃体切除治疗激光笔致儿童全层黄斑裂孔1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 144-147.
[4] 刘南仙,杨泽垠,韩琳,张爱英,赵宇亮,薛静,孙怡君,邵永良. 视频脑电图在儿童复发性眩晕诊断中的意义[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 20-25.
[5] 黄焕,华红利,邓玉琴,江承洋,王雨薇,杨星海. 儿童过敏性鼻炎、扁桃体腺样体肥大和鼻窦炎之间相关性及其对临床指导价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 34-41.
[6] 尹振乾,皇甫辉. 头颈部木村病1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 104-107.
[7] 张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147.
[8] 王华,张丰珍,龙婷,赵靖,李宏彬,王生才,王桂香. 后颅窝肿瘤术后儿童气管切开原因及预后转归分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 168-173.
[9] 乐冰艳,邹剑,雷蕾,文巧,钱应雪. 儿童扁桃体微生物群与免疫调节及疾病关联[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 193-200.
[10] 黄爱萍,王娟,王丽,耿江桥,王亚芳,温鑫. 儿童原发扁桃体Burkitt淋巴瘤累及上颌骨和肺1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 148-152.
[11] 毛一恒,冯洁,何润田. 高血脂对视网膜损害与脉络膜厚度关系研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 162-167.
[12] 曹正勇,李小波. 慢性鼻-鼻窦炎合并哮喘术后短程局部使用糖皮质激素辅助治疗的安全性和有效性[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 43-50.
[13] 刘畅,杨景朴,高雨,王文佳. 长春地区儿童变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 51-58.
[14] 付圣尧,陈敏,庞文会,李娜. 内镜辅助个体化手术入路治疗儿童鼻中线囊肿及瘘管[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 65-71.
[15] 陈丹萍,何子键,虞幼军,周晓娓. 儿童突发性聋10年住院病例的疗效及预后相关因素分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 16-22.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!